Staphylococcus aureus
resistance is a consistent problem with a large impact on the health care system. Infections with resistant
S. aureus
can cause serious adverse effects and can result in death.
Tuberculosis (TB) is among the greatest public health and safety concerns in the 21st century Mycobacterium tuberculosis, which causes TB, infects alveolar macrophages and uses these cells as one of its primary sites of replication. The current TB treatment regimen, which consists of chemotherapy involving a combination of 3-4 antimicrobials for a duration of 6-12 months, is marked with significant side effects, toxicity, and poor compliance. Targeted drug delivery offers a strategy that can overcome many of the problems of current TB treatment by specifically targeting infected macrophages. Recent advances in nanotechnology and material science have opened an avenue to explore drug carriers that actively and passively target macrophages. This approach can increase the drug penetration into macrophages by using ligands on the nanocarrier that interact with specific receptors for macrophages. This review encompasses the recent development of drug carriers specifically targeting macrophages actively and passively. Future directions and challenges associated with development of effective TB treatment are also discussed.
Fatty acid biosynthetic enzymes exploit the reactivity of acyl- and malonyl-thioesters for catalysis. Here we synthesize acetyl/malonyl-CoA analogs with esters or amides in place of the thioester and characterize their behavior as substrates or inhibitors of the E. coli FabH ketosynthase. The acetyl- and malonyl-oxa(dethia)CoA analogs undergo extremely slow hydrolysis in the presence of FabH or C112Q mutant, which mimics the acyl-enzyme intermediate. Decarboxylation of malonyl-oxa(dethia)CoA by FabH or C112Q mutant was not detected. The amide analogs were completely stable to enzyme activity as expected. In enzyme assays, acetyl-oxa(dethia)CoA is surprisingly slightly activating, while acetyl-aza(dethia)CoA is a moderate inhibitor. The malonyl-oxa/aza(dethia)CoAs are inhibitors with Ki’s near the Km of malonyl-CoA. For comparison, we determine the FabH catalyzed decomposition rates for acetyl/malonyl-CoA, revealing some fundamental catalytic traits of FabH. The stable and inhibitory properties of the substrate analogs makes them promising for structure-function studies to undercover the basis of FabH cooperativity and enzyme:substrate interactions.
Fatty
acid and polyketide biosynthetic enzymes exploit the reactivity
of acyl- and malonyl-thioesters for catalysis. A prime example is
FabH, which initiates fatty acid biosynthesis in many bacteria and
plants. FabH performs an acyltransferase reaction with acetyl-CoA
to generate an acetyl-S-FabH acyl-enzyme intermediate
and subsequent decarboxylative Claisen-condensation with a malonyl-thioester
carried by an acyl carrier protein (ACP). We envision that crystal
structures of FabH with substrate analogues can provide insight into
the conformational changes and enzyme/substrate interactions underpinning
the distinct reactions. Here, we synthesize acetyl/malonyl-CoA analogues
with esters or amides in place of the thioester and characterize their
stability and behavior as Escherichia coli FabH substrates or inhibitors to inform structural studies. We also
characterize the analogues with mutant FabH C112Q that mimics the
acyl-enzyme intermediate allowing dissection of the decarboxylation
reaction. The acetyl- and malonyl-oxa(dethia)CoA analogues undergo
extremely slow hydrolysis in the presence of FabH or the C112Q mutant.
Decarboxylation of malonyl-oxa(dethia)CoA by FabH or C112Q mutant
was not detected. The amide analogues were completely stable to enzyme
activity. In enzyme assays with acetyl-CoA and malonyl-CoA (rather
than malonyl-ACP) as substrates, acetyl-oxa(dethia)CoA is surprisingly
slightly activating, while acetyl-aza(dethia)CoA is a moderate inhibitor.
The malonyl-oxa/aza(dethia)CoAs are inhibitors with K
i’s near the K
m of
malonyl-CoA. For comparison, we determine the FabH catalyzed decomposition
rates for acetyl/malonyl-CoA, revealing some fundamental catalytic
traits of FabH, including hysteresis for malonyl-CoA decarboxylation.
The stability and inhibitory properties of the substrate analogues
make them promising for structure–function studies to reveal
fatty acid and polyketide enzyme/substrate interactions.
Methylmalonyl‐CoA epimerase (MMCE) is proposed to use general acid‐base catalysis, but the proposed catalytic glutamic acids are highly asymmetrical in the active site unlike many other racemases. To gain insight into the puzzling relationships between catalytic mechanism, structure, and substrate preference, we solved Streptomyces coelicolor MMCE structures with substrate or 2‐nitropropionyl‐CoA, an intermediate/transition state analogue. Both ligand bound structures have a planar methylmalonate/2‐nitropropionyl moiety indicating a deprotonated C2 with ≥4 Å distances to either catalytic acid. Both glutamates interact with the carboxylate/nitro group, either directly or through other residues. This suggests the proposed catalytic acids sequentially catalyze proton shifts between C2 and carboxylate of the substrate with an enolate intermediate. In addition, our structures provide a platform to design mutations for expanding substrate scope to support combinatorial biosynthesis.
Tuberculosis is one of the most frequent causes of death in humans worldwide. One of the primary reasons tuberculosis remains a public health threat is that diagnosis can take weeks to months, is often not very sensitive and cannot be accomplished in many remote environments. A rapid, sensitive and inexpensive point-of-care (POC) diagnostic would have a major impact on tuberculosis eradication efforts. The tuberculosis diagnostic system REFtb is based on specific detection of the constitutively expressed β-lactamase (BlaC) in Mycobacterium tuberculosis using a custom fluorogenic substrate designated as CDG-3. REFtb has potential as a diagnostic for tuberculosis that could be very inexpensive (<USD 2.00/test), used at the POC and could provide definitive diagnosis within 10 min. However, the reagents for REFtb are currently in liquid form, making them more susceptible to degradation and difficult to transport. We evaluated the improvement in the stability of REFtb reagents by lyophilization under a variety of conditions through their effects on the performance of REFtb. We found that lyophilization of REFtb components produces an easily reconstituted powder that displays similar performance to the liquid system and that lactose represents one of the most promising excipients for use in a final POC REFtb diagnostic system. These studies provide the foundation for the production of a stable POC REFtb system that could be easily distributed worldwide with minimal or no requirement for refrigeration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.